All
FDA to Speed Up Review of Futibatinib to Treat Certain Patients With Cholangiocarcinoma
March 31st 2022The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.
'Give Yourself Grace’ Amidst the Potential Fear of Cancer Recurrence During Survivorship
March 31st 2022As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.
Universal Genetic Testing Should be Recommended for All Patients With Colon Cancer, Says Expert
March 30th 2022Performing genetic testing in every patient diagnosed with colon cancer, and not just those considered high-risk, could identify that person's risk of developing another cancer later in life.
‘Authentically Empathic’ Late-Stage Patient Inspires Fellow Cancer Survivor
March 28th 2022When lovers of “Pinky and the Brain,” “Teenage Mutant Ninja Turtles” and other cartoons gathered in voice actor Rob Paulsen’s hospital room, he took particular notice of one exuberant woman with cancer who was extroverted and kind, despite not having long to live.
FDA Rejects Request to Approve Novel Drug Combination in NSCLC
March 27th 2022The FDA’s decision follows a recommendation from a panel of experts that suggested the agency not approve sintilimab plus the chemotherapy pemetrexed and platinum-based chemotherapy for patients with non-squamous non-small cell lung cancer.
Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer
March 25th 2022AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.